首页> 外文期刊>Expert opinion on investigational drugs >Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes.
【24h】

Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes.

机译:BI-1356对二肽基肽酶4的抑制作用,BI-1356是一种用于治疗2型糖尿病的β细胞衰竭的新药。

获取原文
获取原文并翻译 | 示例
       

摘要

BI 1356, a xanthine-based DPP-4 inhibitor, has reached Phase III trials. The compound efficiently inhibits dipeptidyl peptidase 4 (DPP-4) in vitro and in vivo. In vivo GLP-1 levels increase to levels at or above the levels of other DPP-4 inhibitors. Preclinical trials suggest a once-daily administration of 5 mg to be efficient, long-lasting and without known side effects.
机译:基于黄嘌呤的DPP-4抑制剂BI 1356已进入III期试验。该化合物在体外和体内均能有效抑制二肽基肽酶4(DPP-4)。体内GLP-1水平增加到等于或高于其他DPP-4抑制剂水平的水平。临床前试验表明,每天一次5 mg的给药有效,持久且没有已知的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号